Emergent BioSolutions (EBS) Misses Q1 EPS by 1c, Reaffirms Guidance
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.65 -1.63%
EPS Growth %: -138.7%
Financial Fact:
Interest expense: -2.05M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -138.7%
Financial Fact:
Interest expense: -2.05M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.29, $0.01 worse than the analyst estimate of $0.30. Revenue for the quarter came in at $116.9 million versus the consensus estimate of $116.17 million.
Emergent BioSolutions reaffirmed guidance.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- KB Home (KBH) PT Lowered to $50 at RBC Capital
- Scotiabank Reiterates Sector Outperform Rating on Ero Copper Corp. (ERO:CN) (ERO)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
